Proposal for vaccination against SARS coronavirus using avian infectious bronchitis virus strain H from The Netherlands.
作者信息
Bijlenga G
出版信息
J Infect. 2005 Oct;51(3):263-5. doi: 10.1016/j.jinf.2005.04.010. Epub 2005 Jul 19.
Abstract
摘要
相似文献
1
Proposal for vaccination against SARS coronavirus using avian infectious bronchitis virus strain H from The Netherlands.
J Infect. 2005 Oct;51(3):263-5. doi: 10.1016/j.jinf.2005.04.010. Epub 2005 Jul 19.
2
Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
Avian Pathol. 2003 Dec;32(6):567-82. doi: 10.1080/03079450310001621198.
3
Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
J Virol. 2013 Jun;87(12):6551-9. doi: 10.1128/JVI.00087-13. Epub 2013 Apr 10.
4
Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.
J Virol. 2011 Jan;85(1):217-30. doi: 10.1128/JVI.01805-10. Epub 2010 Oct 27.
5
Development of a SARS vaccine: an industrial perspective on the global race against a global disease.
Expert Rev Vaccines. 2003 Aug;2(4):465-7. doi: 10.1586/14760584.2.4.465.
6
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
Lancet. 2004 Jun 26;363(9427):2122-7. doi: 10.1016/S0140-6736(04)16501-X.
7
Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
J Virol. 2015 Mar;89(6):2995-3007. doi: 10.1128/JVI.02980-14. Epub 2014 Dec 17.
8
Progress towards a SARS vaccine.
Viral Immunol. 2010 Oct;23(5):455. doi: 10.1089/vim.2010.ed.23.5.
9
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
Vaccine. 2008 Dec 2;26(51):6678-84. doi: 10.1016/j.vaccine.2008.09.006.
10
PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
Virol Sin. 2011 Apr;26(2):81-94. doi: 10.1007/s12250-011-3183-z. Epub 2011 Apr 7.
引用本文的文献
1
Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review.
Iran J Public Health. 2020 Oct;49(Suppl 1):18-29. doi: 10.18502/ijph.v49iS1.3666.
2
Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates.
Sci Rep. 2021 Mar 11;11(1):5804. doi: 10.1038/s41598-021-83930-6.
3
An overview of vaccine development for COVID-19.
Ther Deliv. 2021 Mar;12(3):235-244. doi: 10.4155/tde-2020-0129. Epub 2021 Feb 24.
4
Immune response scenario and vaccine development for SARS-CoV-2 infection.
Int Immunopharmacol. 2021 May;94:107439. doi: 10.1016/j.intimp.2021.107439. Epub 2021 Jan 29.
5
Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19.
Curr Microbiol. 2021 Feb;78(2):435-448. doi: 10.1007/s00284-020-02310-x. Epub 2021 Jan 3.
6
COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management.
Front Pharmacol. 2020 Oct 16;11:563478. doi: 10.3389/fphar.2020.563478. eCollection 2020.
7
Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.
Transbound Emerg Dis. 2021 May;68(3):1111-1124. doi: 10.1111/tbed.13804. Epub 2020 Sep 23.
8
COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.
Hum Vaccin Immunother. 2020 Jun 2;16(6):1232-1238. doi: 10.1080/21645515.2020.1735227. Epub 2020 Mar 18.
9
Potential interventions for novel coronavirus in China: A systematic review.
J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707. Epub 2020 Mar 3.
本文引用的文献
1
Development and use of the H strain of avian infectious bronchitis virus from the Netherlands as a vaccine: a review.
Avian Pathol. 2004 Dec;33(6):550-7. doi: 10.1080/03079450400013154.
2
Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.
Nat Med. 2004 Mar;10(3):290-3. doi: 10.1038/nm1001. Epub 2004 Feb 22.
3
Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
Avian Pathol. 2003 Dec;32(6):567-82. doi: 10.1080/03079450310001621198.
4
Mosaic evolution of the severe acute respiratory syndrome coronavirus.
J Virol. 2004 Jan;78(1):76-82. doi: 10.1128/jvi.78.1.76-82.2004.
5
The Genome sequence of the SARS-associated coronavirus.
Science. 2003 May 30;300(5624):1399-404. doi: 10.1126/science.1085953. Epub 2003 May 1.
6
Study of protection by recombinant fowl poxvirus expressing C-terminal nucleocapsid protein of infectious bronchitis virus against challenge.
Avian Dis. 2001 Apr-Jun;45(2):340-8.
7
Adoptive transfer of infectious bronchitis virus primed alphabeta T cells bearing CD8 antigen protects chicks from acute infection.
Virology. 2000 Mar 30;269(1):183-9. doi: 10.1006/viro.2000.0211.
8
Cytotoxic T lymphocyte responses to infectious bronchitis virus infection.
Adv Exp Med Biol. 1998;440:455-60. doi: 10.1007/978-1-4615-5331-1_58.
9
The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection.
J Virol. 1997 Oct;71(10):7889-94. doi: 10.1128/JVI.71.10.7889-7894.1997.
10
Specific cytotoxic T lymphocytes are involved in in vivo clearance of infectious bronchitis virus.
J Virol. 1997 Jul;71(7):5173-7. doi: 10.1128/JVI.71.7.5173-5177.1997.
Zotero 插件